Physician profile
Sandra Danielle Algaze
NPI 1861886707
$8,679.74
in general payments reported to CMS, 2019-2025
22 companies · $7,160 in 2025
The $7,160 reported for 2025 was more than what 78% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $672 · 2020: $388 · 2021: $92.40 · 2023: $344 · 2024: $23.17 · 2025: $7,160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,255 · Food and Beverage: $861 · Travel and Lodging: $385 · Education: $25.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,255.00 |
| Food and Beverage | $861.18 |
| Travel and Lodging | $385.44 |
| Education | $25.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $3,780.00 | 2025 | |
| Incyte Corporation | $3,241.28 | 2020-2025 | Zynyz, Zynyz, Monjuvi |
| Amgen INC. | $414.08 | 2019-2023 | Nplate, Xgeva, Kyprolis |
| Celgene Corporation | $349.42 | 2019-2020 | |
| Sobi, INC | $122.85 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $121.74 | 2019 | |
| Genzyme Corporation | $106.25 | 2020-2025 | |
| Lilly USA, LLC | $71.96 | 2021 | |
| Janssen Biotech, INC. | $69.90 | 2023-2025 | Tecvayli, Darzalex |
| Abbvie INC. | $68.59 | 2019 | |
| Emd Serono, INC. | $63.52 | 2023 | Bavencio |
| Astrazeneca Pharmaceuticals Lp | $47.05 | 2023-2025 | Calquence |
| Caris Mpi, INC. | $35.34 | 2025 | Mi Cancer Seek |
| Merck Sharp & Dohme LLC | $25.70 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $24.41 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $23.17 | 2024 | Brukinsa |
| Alexion Pharmaceuticals, INC. | $21.15 | 2023 | Ultomiris |
| Blueprint Medicines Corporation | $20.80 | 2023 | Ayvakit |
| Bayer Healthcare Pharmaceuticals INC. | $20.44 | 2021 | |
| Jazz Pharmaceuticals INC. | $19.91 | 2020 | |
| Genentech USA, INC. | $19.86 | 2020 | |
| Agios Pharmaceuticals, INC. | $12.32 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Algaze listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.